Shares of Collegium Pharmaceutical Inc. (NASDAQ:COLL) have been assigned an average rating of “Buy” from the seven research firms that are currently covering the company. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $27.00.

COLL has been the topic of a number of recent analyst reports. Jefferies Group reaffirmed a “buy” rating on shares of Collegium Pharmaceutical in a research note on Thursday, September 22nd. Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Collegium Pharmaceutical in a research note on Wednesday, September 14th. Gabelli initiated coverage on Collegium Pharmaceutical in a research note on Tuesday, September 13th. They issued a “buy” rating and a $25.00 price objective on the stock. Piper Jaffray Cos. set a $23.00 price objective on Collegium Pharmaceutical and gave the stock a “buy” rating in a research note on Wednesday, October 12th. Finally, Zacks Investment Research raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday, November 15th.

Collegium Pharmaceutical (NASDAQ:COLL) opened at 17.04 on Tuesday. The stock’s 50 day moving average is $16.64 and its 200 day moving average is $14.13. Collegium Pharmaceutical has a 52 week low of $8.24 and a 52 week high of $30.58. The company’s market capitalization is $399.76 million.

A number of institutional investors have recently modified their holdings of COLL. Goldman Sachs Group Inc. raised its position in shares of Collegium Pharmaceutical by 47.7% in the first quarter. Goldman Sachs Group Inc. now owns 60,294 shares of the specialty pharmaceutical company’s stock valued at $1,094,000 after buying an additional 19,460 shares during the period. LPL Financial LLC increased its stake in Collegium Pharmaceutical by 105.9% in the first quarter. LPL Financial LLC now owns 108,290 shares of the specialty pharmaceutical company’s stock valued at $1,968,000 after buying an additional 55,690 shares in the last quarter. Tocqueville Asset Management L.P. increased its stake in Collegium Pharmaceutical by 18.2% in the second quarter. Tocqueville Asset Management L.P. now owns 51,900 shares of the specialty pharmaceutical company’s stock valued at $615,000 after buying an additional 8,000 shares in the last quarter. California State Teachers Retirement System increased its stake in Collegium Pharmaceutical by 76.0% in the second quarter. California State Teachers Retirement System now owns 28,395 shares of the specialty pharmaceutical company’s stock valued at $336,000 after buying an additional 12,258 shares in the last quarter. Finally, Swiss National Bank purchased a new stake in Collegium Pharmaceutical during the second quarter valued at approximately $212,000. 53.07% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2016/11/25/collegium-pharmaceutical-inc-coll-receives-27-00-consensus-pt-from-brokerages.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza), is an abuse-deterrent, extended-release, oral formulation of oxycodone, a prescribed opioid medication.

5 Day Chart for NASDAQ:COLL

Receive News & Stock Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.